Canagliflozin
- Generic Name
- Canagliflozin
- Brand Names
- Invokamet, Invokana
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25FO5S
- CAS Number
- 842133-18-0
- Unique Ingredient Identifier
- 6S49DGR869
- Background
Canagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise .
It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , .
Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients .
- Indication
This drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus .
Another indication for canagliflozin is the prevention of major cardiovascular events (myocardial infarction, stroke, or death due to a cardiovascular cause) in patients with type 2 diabetes, as well as hospitalization for heart failure in patients with type 2 diabetes.
In addition to the above, canagliflozin can be used to lower the risk of end-stage kidney disease and major increases in serum creatinine and cardiovascular death for patients with a combination of type 2 diabetes mellitus, diabetic nephropathy, and albuminuria.
It is important to note that this drug is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis .
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Major Adverse Cardiac Events, Type 2 Diabetes Mellitus, Doubling of serum creatinine
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2014-04-23
- Target Recruit Count
- 116
- Registration Number
- NCT00963768
Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo of TA-7284
- First Posted Date
- 2008-07-01
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 61
- Registration Number
- NCT00707954
- Locations
- 🇯🇵
P-One Clinic, Hachioji-city, Tokyo-to, Japan
A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2013-05-24
- Target Recruit Count
- 376
- Registration Number
- NCT00650806
An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type IIDiabetes Mellitus, Non Insulin Dependent
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2013-07-19
- Target Recruit Count
- 451
- Registration Number
- NCT00642278
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.